Anavex Life Sciences Corp (AVXL)

[falconer66a]

The potential of Anavex 3-71

First, for myself and many others, I want to commend georgejjl for his always-informative and detailed posts; information buried in the dozens of papers and studies on Anavex molecules. George, you so helpfully pull out and post the most information needed to understand the deep science of Anavex. Your postings continue to highlight and validate the science that will make Anavex Life Sciences Corp a major pharmaceutical in a few years. Our thanks.

For example, your new post included this:

...AF710B [Anavex 3-71] is an allosteric M1 receptor agonist. Its heteromer-specific effects differentiate it from other M1 agonists and modulators. Fisher claimed that the new compound is exquisitely potent, acting as a cognitive enhancer in rats at 1 to 30 micrograms (not milligrams) per kilogram body weight. According to Fisher, the compound is orally available with a safety margin of more than 50,000 times the minimally active dose. “Those are orders of magnitude more potent than donepezil and other agonists acting either on the M1 or the s-1 receptors, respectively,” Fisher said.

Understandably, the prime focus by Anavex has been with blarcamesine, the company’s lead new drug. Doubtless, it will be big, for Rett syndrome, Parkinson’s disease dementia, and for Alzheimer’s—as the trials for those diseases will reveal. But, as the above quote notes, Anavex 3-71 will likely be even stronger and safer. Patients will be getting doses measured in micrograms, not the milligrams of blarcamesine. A microgram is one one-thousandth of a milligram. Dosages of Anavex 3-71 will be generally three orders of magnitude lower than blarcamesine, with safety up to more than 50,000 times the minimally-active dose.

As noted previously, blarcamesine, against Alzheimer’s, is effective in about 80% of those with the disease. They have genetics that favor blarcamesine function. But, there is the distinct possibility that Anavex 3-71 could make up the difference, working well in those with unfavorable blarcamesine genetics. Or (very likely), Anavex 3-71 may replace blarcamesine altogether. Future trials will determine this. The molecule’s safety and tiny effective doses strongly suggest it.

Lastly, of course, will be prophylactic use of either drug; to prevent the onset of a diversity of age-related diseases and conditions. Anavex 3-71 will be a strong candidate for this. Trials will test and prove....